Comparison · NCT00404924-fe42213a
Vandetanib 300 mg vs Placebo: Objective Response Rate (ORR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib 300 mg vs Placebo: Objective Response Rate (ORR). Trial comparisons, record NCT00404924-fe42213a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00404924-fe42213a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0259 | 0.016 | 0.0417 | wilson | |
| Risk in group 2 | 0.00651 | 0.00179 | 0.0234 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0194 | -0.000193 | 0.0359 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.98 | 0.921 | 17.2 | log | |
| Odds ratio, group 1 over group 2 | 4.06 | 0.928 | 17.8 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib 300 mg than on Placebo | 51.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib 300 mg | vandetanib (300 mg daily) plus best supportive care | 16 | 617 | OG000 |
| Group 2 | Placebo | Placebo plus best supportive care | 2 | 307 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Objective Response Rate (ORR)
- Description
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria.~The categories for best objective response are CR, PR, stable disease (SD)\>= 8 weeks, progressive disease (PD) or NE.
- Time frame
Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 8 weeks from randomisation until objective disease progression.
- Population
Source ClinicalTrials.gov
Trial
- Title
- ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
- NCT number
- NCT00404924
- Phases
- PHASE3
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- ZD6474 (vandetanib), Best Supportive Care
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2012-03-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00404924?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00404924-fe42213a